This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Ca…

Pancreatic Ductal Adenocarcinoma (PDAC)G12D Mutated KRAS

~Estimated

~$10 – $8,750

Verastem, Inc.NCT07644559

Phase 1

A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal Cancer+2 more

~Estimated

~$10 – $8,750

Verastem, Inc.NCT07020221